Recordati Seeks Ex-Italy Growth In Orphan Drugs, Emerging Markets And OTCs
This article was originally published in PharmAsia News
Italy’s Recordati plans to globalize its orphan drugs business and will target Russia, Turkey and markets in Central and Eastern Europe for its primary care prescription and OTC products.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
Although top-line efficacy results from a small study in critically ill patients with COVID-19 suggest there are therapeutic benefits associated with Relief Therapeutics/NeuroRx’s RLF-100 (aviptadil), further data are awaited from the results of a randomized clinical trial, expected later this year.